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DIGITOXIN-A CRITICAL REVIEW*
WILLIAM C. DIEFENBACH AND JOHN K. MENEELY, JR.
Within recent years, there has been an increasing interest in purified
digitalis preparations. However, in spite of the original optimistic re-
ports, the recent literature tends to discredit the value of the new prepa-
rations. Mostcriticisms fall into two groups: (A) Inadequacy ofdigitali-
zation with the original recommended dosage schedules. (B) Increase
in the incidence ofdrugtoxicity. Itis the purposeofthis paper to analyze
the value of the most commonly used purified glycoside, digitoxin.
History
Modern concepts of digitalis therapy began in 1785, with the pub-
lication byWilliamWitheringofhisclassicalmonograph,86 AnAccount
of Foxglove and Some of Its Medical Uses, with Practical Remarks on
Dropsy and Other Diseases. Withering, a botanist as well as aphysician,
recognized that the amount of active material present in the plant was
not constant, and he emphasized the importance of controlling the con-
ditions ofgrowth of the plant and the importance of proper selection of
the leaves. Hecautioned against using the roots because he had observed
a great variation in the potency of material obtained from that source.
During most of the 19th century Withering's advice was little heeded;
purplefoxglove was often prescribed indiscriminately and in toxic doses.
But the striking clinical results sometimes obtained with such crude
preparations stimulatedchemiststo begin thesearchfor activeprinciples.
Thefirststudies recorded arethoseofthe Frenchchemist,Destouches,
in 1808, and Quevenue and Homolle, in 1842, who probably already
had digitoxin present in their digitaline preparations. In 1868,
Nativelle62' 63 isolated from the dried leaves of Digitalis purpurea a
relatively pure cardio-active principle, which was given the name of
digitaline cristallisee, and was proved to be a potent cardiac drug by
Vulpian. It has been marketed in France by the name of digitaline
Nativelle. In 1875, the German chemist Schmiedeberg reported70 the
isolation of a closely allied material, which he named digitoxin, and
stated that it formed the bulk of digitaline cristallisee. Windaus,85 in
1926, completed the analytical investigation ofdigitoxin by determining
its empirical formula and by interpreting its behavior on hydrolysis.
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Opinions vary about whether or not these two substances are the same.
While Weese82 refers to them as identical, Jacobs48 believes thatthe two
products are not exactly the same and states that digitoxin is the chief
constituent, probably at least 90 per cent of the original digitaline cris-
tallisee of Nativelle. New and Non-official Remedies uses the names
digitaline cristallisee (Nativelle) and digitoxin interchangeably. The
United States Pharmacopceia also treats them as if they were the same.
However, there is some belief16' 24, 30, 41, 61 that preparations of digi-
taline cristallisee (Nativelle) and digitoxin differ in potency.
Pharmacology
At thepresent time,there is nosyntheticcardiacglycoside forclinical
use; all now sold are derived from the crude drugs. The chemical isola-
tion of these pure principles is not a simple process; the final yield of
glycoside is between ninety and one hundred per cent chemically
23, 48, 76 pure.
The empiric formula of digitaline Nativelle closely approximates
C41H64013. It appears as thin colorless, odorless, elongated, rectangular
platelike crystals with a bitter taste and a melting point between 2530
to 263°C. It is practically insoluble in water, ether, and glycerin, and is
soluble in acetone, chloroform, ethyl alcohol, and pyridine. It is stand-
ardized by the intravenous method of Hatcher and Brody,46 so that 0.42
mg. equal one cat unit, but the therapeutic dose is much less than that
of digitalis measured in cat units. The action of digitoxin is like that of
digitalis, but is more persistent. The preparations available are in the
form oftablets containing 0.05, 0.01, and 0.2 mg. of the active principle
and in 2 cc. and 1 cc. ampoules containing 0.4 and 0.2 mg. respectively.
Digitoxin has been shown to be completely absorbed from the gastro-
intestinal tract in animals and human beings.13 15 19, 36 45' 14 For that
reason, the oral and intravenous doses are the same.80 If the decline in
the ventricular rate is used to judge the oral absorption of digitoxin, it
is complete in from 4 to 10 hours.40 80 On intravenous injection, the
initial effects were noted in from 25 minutes to 2 hours, with maximum
effects in 2 to 9 hours. The effect begins to regress in 2 or 3 days, the
total duration of action lasting approximately 2 weeks.20' 22, 30, 35, 41
When given subcutaneously or intramuscularly, there may be consid-
erable pain and local reaction. Sterile abscesses may result. Digitoxin is
readily absorbed from the large bowel, and rectal administration is also
a valid means of administering the drug. The fate of digitoxin, as with
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digitalis, within the body is unknown. Ninety per cent of the drug is
taken up by the extracardial tissues, especially the liver and skeletal
muscles. Gram for gram, the heart muscle absorbs more than does any
other organ in the body. Because of the persistence of the cardiac action
of digitoxin after its administration is discontinued, it is essential to
obtain a history of previous digitalis before further administration of the
drug. Small amounts of the drug are excreted, unchanged, in the bile
and urine.
The potency of 1 mg. of digitoxin is approximately equal to 1000
mg. (gr. 1.5) of U.S.P. XII digitalis powder and to 1 U.S.P. XII Digi-
talis Unit. A dose of 1.25 mg. of digitoxin induces the same degree of
reduction of ventricular rate as 1.25 gm., or 16.3 cat units of whole-leaf
digitalis. There is a slower rate of dissipation, and hence toxicity is more
prolonged.4 Nosignificant difference hasbeenfound in the ratio between
the toxic and therapeutic doses for digitoxin as compared to digi-
talis.38 89, 42, 54, 59
Digitoxin, in patients with congestive failure, results in an increased
cardiac output, a decrease in arteriovenous oxygen difference,6, 31, 44, 50.
52, 53. 56, 57, 66, 71, 72, 74 lowered venos pressure,12 21, 32, 35, 52, 57, 72, 74, 75, 87 a
faster circulation time,32' 52, 74, 7 87 and a diminished blood volume.11 58
After digitalization, the vital capacity is increased,72' 7 the respiratory
minute volume is reduced,9 44 7 and the alveolar carbon dioxide is in-
creased.71 The basal metabolic rate falls,71' 7 and there is decreased
oxygen debt after exercise.65 There is a slowing of the pulse rate in
patients with auricular fibrillation and in those cases of congestive fail-
ure with a sinus tachycardia. This is brought about both by a vagal
stimulation, which may beobliterated by atropine, and by a direct action
on the nodal tissues and myocardium, which cannot be obliterated by
atropine. Controversy still exists as to the exact mechanism of the action
of digitalis. The theory of hepatic vein constriction probably does not
apply in man.2'69 The action of digitoxin is primarily on the myo-
cardium,1 22, 25, 26,27,35 as the effect on the vagus and on the conducting
tissue does not account entirely for the beneficial response which may
occur before or without a change in rate. Boyer and Poindexter"0 stated
that the beneficial effect may be brought about in part by a cortin-like
action on the myocardium, whereby potassium is maintained within the
cell, and cell hydration is improved.
Therapeutically, the most important use ofdigitoxin is in congestive
heart failure. It is useful regardless of whether the failure is predomi-
nantly of the right or left ventricle or both. The etiology of the heart
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failure modifies the response to the drug. The best results are obtained
when failure is due to hypertensive or arteriosclerotic heart disease. De-
compensation due to severe rheumatic myocarditis, cardiovascular
syphilis, toxic myocarditis, myxedema, hyperthyroidism, and thiamine
deficiency is less responsive, if at all. Digitoxin is also indicated in
auricular fibrillation and auricular flutter if failure is present. It is not
contra-indicated in heart block when failure is present.' " Sometimes
it is successful in the treatment of paroxysmal tachycardia."4 87 In coro-
nary thrombosis with failure, it is indicated, but must be carefully regu-
lated, and rapid digitalization is unwise. There is increased sensitivity
of the injured myocardium to the drug.3,29 81, 8 Travell et al.81 reported
that in a cat, ligation of a single coronary artery caused a reduction of
25 per cent in the fatal dose of digitalis. If coronary flow is diminished,
less than an average therapeutic dose of the glycoside may cause toxic
symptoms. In heart failure due to shock, cardiac compression from peri-
cardial effusion or constricting adhesions, or in peripheral circulatory
collapse as a result of acute infectious disease, the drug is of no value.
It does not increase coronary blood flow and is not indicated in angina
pectoris without failure.8 33, 34
Toxicity
Digitoxin, when given in recommended dosage and despite care,
frequentlyproduces signs andsymptoms ofoverdosage. The toxic actions
ofdigitoxin were first observed byKoppe,51 who took 3.5 mg. in 5 days,
suffered severe toxic symptoms, with nausea and vomiting, slowing of
the pulse rate from 80 to 40, and a bigeminal rhythm that became
grosslyirregular. Serious toxic manifestations seemtobemore frequently
observed with the use of the digitalis glycosides than from the whole-
leaf preparations,28' 47, 68, 84 and the incidence of toxicity has risen in
direct relation to the increased use of these glycosides.47
The toxic symptoms and signs with variable dosage are different in
different individuals. The resultant symptoms are due to continued in-
gestion of the drug in amounts greater than can be destroyed or elimi-
nated from the body. There is an accumulation of the drug in the body,
and among the earliest symptoms noted with digitoxin overdosage is
anorexia, which usually appears before the nausea and vomiting.
Diarrhea andabdominal painsoccasionally occur. Withdigitoxinpoison-
ing almost every clinically known type of cardiac arrhythmia can occur,
i.e., sinus arrhythmia, premature contractions, bigeminy, trigeminy,
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auricular fibrillation, auriculoventricular block, sinus bradycardia, par-
oxysmal auricular tachycardia and ventricularfibrillation. Digitoxin
effect on the electrocardiogram is demonstrated by T wave changes,
RS-T interval depression, P-R interval prolongation, and Q-T time
shortening.
Rarely one sees the cerebral symptoms of overdosage such as con-
vulsions, aphasia, and delirium, rather more commonly headache,
fatigue, malaise, confusion, drowsiness, and disorientation. Visual dis-
turbances are uncommon, but there may be blurring or disturbances
of color vision in which objects appear yellow and green, less
frequently blue and red. Amblyopia, scotomata, and diplopia may
occur. Sensitivity to digitalis leaf is rarely reported and may be urticarial
or scarlatiniform in character, accompanied by an eosinophilia. It has
not been reported with digitoxin.
Therefore, whenever digitoxin is used, the appearance of signs of
cardiac disorder must be watched for carefully, not only clinically, but
with the aid of the electrocardiogram, and such appearance should call
for the immediate discontinuance of the drug. Toxic symptoms may per-
sist for aweek or more.18, 55, 77, 84
Clinical use
Most patients receiving digitalis continue to require the drug for the
remainder of their lives. After digitalization has been attained, the drug
must begiven daily in order to maintain the beneficial effect. A sufficient
amount must be given to replace that which is eliminated and destroyed
by the body. Wide variations exist from patient to patient regarding the
maintenance dose, and that dose seems to bear no relation to body
weight, or to type or severity of heart failure. The rate of excretion
varies from day to day and from person to person, depending upon the
amount of the drug within the body. It has been shown that the patient
does not excrete a fixed amount each day, regardless of the dose given,
but, rather, a certain fraction of the amount present in the body. An
equilibrium becomes established between the amount ofthe drug within
the body and the rate of elimination. The excretion rate is limited, how-
ever, and, with excessive doses, the drug accumulates in the body to a
point where toxic symptoms occur. One seeks to give an amount which
will restore the highest degree of cardiac efficiency and relieve all symp-
toms and signs of heart failure, and sometimes this dose borders on the
toxic.5' 17, 37, 49
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Stroud and Vander Veer78 observed that with digitoxin, the digitaliz-
ing dose, when given orally over a period of from 3 to 6 days, was be-
tween 1.3 to 2.2 mg. The average maintenance dose was 0.1 mg. daily.
Gold et al."9 41 demonstrated that a single oral or intravenous dose of
1.2 mg. digitalized the majority of patients, with 0.2 mg. daily for
maintenance. Complete digitalization on this schedule was achieved,
however, in only about three-fourths ofthe cases. Themaintenance dose,
after digitalization, depends upon the individual response. Fifty per cent
of patients can be maintained with a daily dose of 0.1 mg.4 Of the re-
mainder about one-half require more and half require less. One does
occasionally encounter a patient who does not tolerate any dose.
It was the impression at the Albany Hospital that there were more
cases of poisoning from digitoxin than there had been with the whole-
leaf preparations. We, therefore, selected 100 cbnsecutive cases which
had been adequately digitalized with digitoxin and had been followed
for from 3 months to 2 years. Twenty of these cases developed toxic
symptoms. They are presented in the accompanying table. As the cases
of digitoxin poisoning demonstrate, they do not differ from poisoning
with other types of digitalis. The toxic manifestations did persist longer,
however, because of the greater cumulative action of the drug. From our
experience, it would seem that considerable caution needs to be exer-
cised in the treatment of patients with congestive heart failure with the
digitoxin preparations. Purified glycosides will not result in more effi-
cient or safer digitalization if administered haphazardly.
As has been pointed out by DeGraff, Batterman, and Rose,18 the
response of a patient to digitalis depends upon the degree of congestive
failure, the theoretical maximum improvement possible, depending
upon the underlying heart disease, and the precipitating cause of heart
failure. The dose required for this response cannot be predicted. It varies
with the same patient from time to time. Giving an average dose may
incompletely digitalize, but far more serious are those cases developing
toxic symptoms from the "average dose." Adequate digitalization aims
to restore cardiac function as quickly and efficiently as possible. Using
the therapeutic response as aguide in giving multiple doses, i.e., 0.4 mg.
every 6 hours until the desired effects are attained, one achieves an
optimum response more frequently than with either insufficient or over
digitalization. Initial digitalization in our experience is best attained
with the modified Eggleston method,19 consisting of multiple doses.
Full digitalization is not obtained in most cases when 1.2 mg. are given
orally or intravenously in single or divided doses during the initial
428DIGITOXIN-A CRITICAL REVIEW
24-hour period.4 18, 68, DeGraff, Batterman, and Rose18 have shown
that the average therapeutic dose for the multiple dose method is 2.2
mg., as compared with 1.7 mg. for the single undivided dose. Our
studies agree with those of Batterman and DeGraff,4 who demonstrated
that the bestoverall maintenance dose is 0.1 mg. They reported 37.5 per
cent toxicity when 0.2 mg. were givendaily.
Discussion
There is no question but that digitoxin offers certain advantages. It
is a stable, pure chemical, and does not require bio-assay. It is completely
absorbed from thegastro-intestinal tract, so thatthe oral and intravenous
doses are the same and interchangeable. The small amount of the drug
necessary for digitalization permits administration of a large fraction in
a single dose, with only a small incidence of local gastro-intestinal
irritation. The rapid onset of action produces quick digitalization by the
oral route so that intravenous administration is rarely necessary. There
is some evidence that various preparations of digitoxin differ in potency;
therefore, as with the whole-leaf digitalis, it is advisable for physicians
to use a single preparation with whose action and potency they are
familiar. The cost ofdigitoxin is no longer appreciably greater than that
of the whole-leaf digitalis. However, the variability in response to fixed
amounts of the drug and the relatively high incidence of toxicity to the
generally accepted maintenance dose impose marked limitations on its
use. It is probably not the drug of choice for routine digitalization.
Summary and conclusions
1. The history, pharmacology, and toxicity of digitoxin are briefly
presented.
2. In a follow-up study of from 3 months to 2 years of 100 consecu-
tive patients in congestive heart failure treated with digitoxin, we have
observed toxic symptoms in 20 per cent of the cases. Twenty cases of
toxicity are presented briefly.
3. The toxic symptoms appear more frequently with digitoxin than
with whole-leaf digitalis, and the toxic manifestations are more pro-
longed.
4. In most patients 1.2 mg. of digitoxin given in the first 24 hours
are not sufficient to achieve adequate digitalization. With adequately
digitalized patients 0.2 mg. results in a higher percentage of toxic symp-
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toms and for that reason 0.05 or 0.1 mg. is more satisfactory for main.
tenance.
5. Reasons are presented for selection of the multiple dose method
as the one of choice for adequate digitalization.
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